Projected clinical outcomes of glaucoma screening in African American individuals

Archives of Ophthalmology

Volumn 130, Issue 3, 2012, Pages 365-372

  Ladapo, Joseph A ^a,b,g   Kymes, Steven M ^e   Ladapo, Jonathan A ^f   Nwosu, Veronica C ^f   Pasquale, Louis R ^b,c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; BLINDNESS; COST BENEFIT ANALYSIS; DISEASE COURSE; EYE EXAMINATION; FREQUENCY DOUBLING TECHNOLOGY; GLAUCOMA; HEALTH CARE POLICY; HUMAN; OUTCOME ASSESSMENT; PERIMETRY; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; VISUAL ACUITY; VISUAL IMPAIRMENT;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; BLINDNESS; GLAUCOMA; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; PREVALENCE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84858602629     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopthalmol.2011.1224     Document Type: Article

References (47)

1. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113-1124.
2. Friedman DS, Wolfs RC, O'Colmain BJ, et al Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538. (Pubitemid 38456289)
3. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005;331(7509):134.
4. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
5. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary openangle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254-4261. (Pubitemid 46579346)
6. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
7. Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985;99(4):383-387. (Pubitemid 15034497)
8. Friedman DS. Issues in screening for glaucoma. Ophthalmic Epidemiol. 2007;14 (3):101-102. (Pubitemid 47026987)
9. Quigley HA. Current and future approaches to glaucoma screening. J Glaucoma. 1998;7(3):210-220. (Pubitemid 28301630)
10. Medicare's glaucoma tests coverage. Medicare.gov Web site. http://www.medicare.gov/navigation/manage-your-health/preventive-services/ glaucoma-tests.aspx. Accessed August 3, 2010.
11. Fleming C, Whitlock EP, Beil T, Smit B, Harris RP. Screening for primary openangle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. Ann Fam Med. 2005;3(2):167-170. (Pubitemid 40477703)
12. Hatt S, Wormald R, Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev. 2006;(4):CD006129.
13. Javitt J, Lee P, Lum F. The value of regular examinations to detect glaucoma and other chronic conditions among older Americans. Ophthalmology. 2007;114(5):833-834. (Pubitemid 46635865)
14. Mills RP. Glaucoma screening: the value is in the details. Am J Ophthalmol. 2008;145(1):3-4. (Pubitemid 350265768)
15. Maul EA, Jampel HD. Glaucoma screening in the real world. Ophthalmology. 2010; 117(9):1665-1666.
16. Hunink MGM. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, NY: Cambridge University Press; 2001.
17. Congdon N, O'Colmain B, Klaver CC, et al Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. (Pubitemid 38456282)
18. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38(1):83-91. (Pubitemid 27051527)
19. Burr JM, Mowatt G, Hernández R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(41):iii-iv, ix-x, 1-190.
20. Physician fee schedule relative value files. Centers for Medicare & Medicaid Services. http://www.cms.hhs.gov/PhysicianFeeSched/PFSRVF/list. asp#TopOfPage. Accessed April 27, 2007.
21. Arias E, Rostron BL, Tejada-Vera B. United States life tables, 2005. Natl Vital Stat Rep. 2010;58(10):1-132.
22. Mowatt G, Burr JM, Cook JA, et al OAG Screening Project. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2008;49(12):5373-5385.
23. Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin North Am. 2003;16(2):213-225. (Pubitemid 36666041)
24. Nehmad L, Madonna RJ. Optimizing the use of frequency doubling technology perimetry in community vision screenings. Optom Vis Sci. 2008;85(7):559-565.
25. Frequency Doubling Technology (FDT) perimetry. Imaging and Perimetry Society Web site. http://webeye.ophth.uiowa.edu/ips/PerimetryHistory/FDP/index. htm. Accessed December 28, 2010.
26. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279. (Pubitemid 36105431)
27. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498-505.
28. World Health Organization. Application of the International Classification of Diseases to Neurology: ICD-NA. 2nd ed. Geneva, Switzerland: World Health Organization; 1997.
29. Kuntz KM, Weinstein MC. Modeling in economic evaluation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory With Practice. New York, NY: Oxford University Press; 2001:150-152.
30. Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association between the use of glaucoma medications and mortality. Arch Ophthalmol. 2010;128(2):235-240.
31. Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with mortality: ameta-analysis of observational studies. Arch Ophthalmol. 2009;127(2):204-210.
32. Kymes SM, Lee BS. Preference-based quality of life measures in people with visual impairment. Optom Vis Sci. 2007;84(8):809-816. (Pubitemid 47262992)
33. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48-56. (Pubitemid 36401765)
34. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487-497.
35. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a costeffectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006;141(6):997-1008.
36. Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology. 2009;116(5):823-832.
37. Parrish RK II, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115(11):1447-1455. (Pubitemid 28055876)
38. McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R; Los Angeles Latino Eye Study Group. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(6):941-948.
39. Atkin WS, Edwards R, Kralj-Hans I, et al UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-1633.
40. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317(7154):307-312. (Pubitemid 28353824)
41. Humphrey L, Chan BKS, Detlefsen S, Helfand M. Screening for Breast Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2010.
42. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000; 283(7):889-896. (Pubitemid 30102129)
43. Broman AT, Quigley HA, West SK, et al. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008;49(1):66-76.
44. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12-19. (Pubitemid 43063883)
45. Wilson MR, Kosoko O, Cowan CL Jr, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol. 2002;134(3):399-405.
46. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760. (Pubitemid 44920172)
47. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544-550. (Pubitemid 46596727)